Bleeding risk in female patients undergoing intravesical injection of onabotulinumtoxinA for overactive bladder: a Danish retrospective cohort study
ConclusionsWe suggest that BTX-A treatments might be classified as low-risk procedures. Discontinuation of antithrombotic therapy is not required in the perioperative management of this patient group.
Source: International Urogynecology Journal and Pelvic Floor Dysfunction - Category: OBGYN Source Type: research
More News: Allergy | Bleeding | Botox | Denmark Health | OBGYN | Overactive Bladder | Overactive Bladder Syndrome | Study